The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.
At Multiple Sclerosis News Today, stories about the keto diet, myelin repair, and vitamin D topped this year's most-read list ...
Exclusive: Scientists uncovered biological strands using artificial intelligence and hope discovery will revolutionise treatment ...
Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple sclerosis and is facing a delayed U.S. approval decision in another form of the ...
Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...
Sanofi (NASDAQ:SNY) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. Sanofi (NASDAQ:SNY) said on ...
The SPRINT-MS trial evaluated the novel drug ibudilast over 96 weeks in patients with primary and secondary progressive multiple sclerosis. The SPRINT-MS trial was a phase II clinical trial of ...
Breakthrough MS study identifies two new types in hopes for treatment - Two new sub-types of multiple sclerosis (MS) were ...
Early studies of biotin as a treatment for multiple sclerosis (MS) were promising, showing that it was well tolerated and brought sustained reversal of MS-related disability. More recent studies, ...
Constipation — having bowel movements less often than usual or stools that are hard or difficult to pass — can affect how you feel throughout your day, disrupt routines, and make other multiple ...
The role of imaging in diagnosing progressive multiple sclerosis (MS) and in assessing prognosis is the subject of a new review. MRI is central in the diagnostic workup of patients suspected of having ...
Most disability accumulation in relapsing multiple sclerosis (MS) is not associated with overt relapses, challenging the current clinical distinction of relapsing and progressive forms of the disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback